Sectra Signs Enterprise Imaging Contract with One of the Larger Multi-Regional Healthcare Systems in the United States

nternational medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide Sectra One Cloud, its enterprise imaging cloud subscription service for diagnostic imaging, to a US-based health system serving a multi-million strong patient community.

Sectra will, as the sole imaging IT provider oversee and deliver the end-to-end infrastructure through a turnkey, fully managed SaaS agreement. Expanding on Sectra’s previously implemented solution for Ophthalmology this enterprise imaging solution will initially be leveraged by the health system’s Radiology service teams and over time into additional imaging service lines including Pathology, Cardiology and Orthopaedics. The cloud solution will be operated in Microsoft Azure as part of a sub-contract agreement with Microsoft managed by Sectra.

“Health systems are under tremendous pressure to maintain patient excellence while balancing growing financial and staffing concerns,” shared Isaac Zaworski, the President of Sectra, Inc. “Regardless of size or infrastructure challenges, Sectra is focused on driving down the costs and complexity of traditional on-premise solutions with highly scalable, high-performance enterprise imaging solutions as a service. We are thrilled for the opportunity to help this health leader execute a long-term multi-departmental imaging strategy as they focus on growing quality and sustainability in their health system.”

The contracted order value for the implementation and use of subscription service until 2033 initially amounts to 227 million dollars, if the full term of the contract is realized, and does not include   expansion plans into additional imaging service lines including, Pathology, Cardiology and Orthopaedics. The agreement was signed in June 2023 and is recognized in order bookings for the first quarter of the 2023/2024 fiscal year.

Sectra One Cloud

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”